Drugs / Venetoclax
Venetoclax
Drug FDA approvedB-cell lymphoma-2 (BCL-2) inhibitor·First approved·2016
- Registered trials
- 575
- Ongoing
- 363/ 63%
- Completed
- 103
- Indications
- 4
Approved indications
| Indication |
|---|
| Chronic lymphocytic leukemia (CLL) |
| Small lymphocytic lymphoma (SLL) |
| "Newly diagnosed AML in adults >=75 years or with comorbidities precluding intensive induction chemotherapy |
| in combination regimens" |
Clinical trial landscape
575 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 212 | 156 | 30 | |
| Phase 1 | 148 | 68 | 43 | |
| Phase 1/2 | 104 | 59 | 12 | |
| Phase 3 | 53 | 36 | 13 | |
| Not applicable | 19 | 16 | 1 | |
| Unknown | 15 | 7 | 2 | |
| Phase 2/3 | 13 | 12 | 0 | |
| Phase 4 | 6 | 5 | 1 | |
| Early Phase 1 | 5 | 4 | 1 | |
| All phases | 575 | 363 | 103 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Selective inhibition of anti-apoptotic BCL-2 pathway to promote tumor cell apoptosis.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.